This study involves people who have obesity or are overweight and also have osteoarthritis of the knee. Osteoarthritis is a condition where the cushioning cartilage in the joints wears down over time, causing pain and stiffness. The study will test a medicine called Orforglipron, which is also known by its code name LY3502970. This medicine comes in tablet form and is taken by mouth once daily. Some people in the study will receive Orforglipron while others will receive placebo. The purpose of the study is to find out if Orforglipron is better than placebo at reducing knee pain in people who have both weight problems and knee osteoarthritis.
During the study, people will take either Orforglipron tablets or placebo tablets once each day for up to 72 weeks. The study will measure knee pain using a scoring system that asks questions about pain levels during different activities. Doctors will compare the changes in pain scores between people taking Orforglipron and those taking placebo to see if the medicine helps reduce knee pain. People in the study will need to be willing to stop taking certain pain medications throughout the entire study period.
The study is designed to help researchers understand whether this new medicine can help people who struggle with both excess weight and painful knee osteoarthritis. People joining the study should have tried to lose weight through diet at least once before without success. The study will look at how safe the medicine is and whether it works well for reducing the knee pain that comes with osteoarthritis in people who are overweight or have obesity.
Germany 
Spain 
